MedTrace Logo

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

NCT00567112 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-03-23

Study results available
· View outcomes & findings →

Summary

A study to compare the pharmacokinetics (PK) of the dry filled capsule (DFC) \& oral compressed tablet (OCT) formulations of MK-0941-009 \& to assess the effect of food on the OCT formulation.

Conditions

Interventions

DRUG

10 mg MK-0941 DFC (fasted)

single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state

DRUG

10 mg MK-0941 OCT (after meal)

single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal

DRUG

10 mg MK-0941 OCT (before meal)

single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast

DRUG

10 mg MK-0941 OCT (fasted)

single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-02-29
Completion
2008-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567112 on ClinicalTrials.gov